Madrigal Pharmaceuticals Inc (MDGL)
204.69
-13.58
(-6.22%)
USD |
NASDAQ |
Apr 24, 16:00
204.69
0.00 (0.00%)
After-Hours: 20:00
Madrigal Pharmaceuticals Enterprise Value: 3.824B for April 23, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 23, 2024 | 3.824B |
| April 22, 2024 | 3.729B |
| April 19, 2024 | 3.700B |
| April 18, 2024 | 3.904B |
| April 17, 2024 | 4.025B |
| April 16, 2024 | 4.117B |
| April 15, 2024 | 4.085B |
| April 12, 2024 | 4.189B |
| April 11, 2024 | 4.362B |
| April 10, 2024 | 4.350B |
| April 09, 2024 | 4.443B |
| April 08, 2024 | 4.429B |
| April 05, 2024 | 4.317B |
| April 04, 2024 | 4.286B |
| April 03, 2024 | 4.361B |
| April 02, 2024 | 4.346B |
| April 01, 2024 | 4.570B |
| March 28, 2024 | 4.795B |
| March 27, 2024 | 4.631B |
| March 26, 2024 | 4.408B |
| March 25, 2024 | 4.408B |
| March 22, 2024 | 4.420B |
| March 21, 2024 | 4.561B |
| March 20, 2024 | 4.635B |
| March 19, 2024 | 4.768B |
| Date | Value |
|---|---|
| March 18, 2024 | 5.117B |
| March 15, 2024 | 4.861B |
| March 14, 2024 | 4.328B |
| March 13, 2024 | 4.913B |
| March 12, 2024 | 4.708B |
| March 11, 2024 | 4.658B |
| March 08, 2024 | 4.562B |
| March 07, 2024 | 4.476B |
| March 06, 2024 | 4.603B |
| March 05, 2024 | 4.426B |
| March 04, 2024 | 4.387B |
| March 01, 2024 | 4.488B |
| February 29, 2024 | 4.181B |
| February 28, 2024 | 4.540B |
| February 27, 2024 | 4.253B |
| February 26, 2024 | 4.109B |
| February 23, 2024 | 4.188B |
| February 22, 2024 | 4.426B |
| February 21, 2024 | 4.018B |
| February 20, 2024 | 4.047B |
| February 16, 2024 | 4.115B |
| February 15, 2024 | 3.898B |
| February 14, 2024 | 3.814B |
| February 13, 2024 | 3.552B |
| February 12, 2024 | 3.781B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
519.25M
Minimum
Apr 03 2020
5.459B
Maximum
Apr 28 2023
1.946B
Average
1.281B
Median
Enterprise Value Benchmarks
| Eli Lilly and Co | 731.37B |
| Viking Therapeutics Inc | 6.163B |
| Akero Therapeutics Inc | 922.85M |
| 89bio Inc | 295.33M |
| Geron Corp | 1.659B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -112.19M |
| Total Expenses (Quarterly) | 117.18M |
| EPS Diluted (Quarterly) | -5.72 |
| Earnings Yield | -9.76% |
| Normalized Earnings Yield | -17.10 |